Children with Peanut Allergy
Conditions
Interventions
Trade Name: All information as per the Q2788g trial CTA 00101/0554/004. Please see letter allowing cross reference of that CTA to this one
Pharmaceutical Form:
Pharmaceutical form of the placebo: Sol
Sponsors
Food Standards Agency
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children taking part in the Genentech Q2788g trial (CTA 00101/0554/004 who provide the additional consent required Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Children unable to provide the correct amounts of blood or who do not consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To discover whether Omalizumab treatment which may decrease reactions to peanuts in peanut allergic individuals, alter T cell responses to peanuts. We wish to find out whether Omalizumab might alter the long tern response of the immune system to peanuts;Secondary Objective: ;Primary end point(s): Examine the in vivo effects of monoclonal anti-IgE on peanut specific T cell responses in a clinical trial designed to treat peanut allergy | — |
Countries
United Kingdom
Outcome results
None listed